



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the [Library Thesis Consent Form](#) and [Deposit Licence](#).

Note : Masters Theses

The digital copy of a masters thesis is as submitted for examination and contains no corrections. The print copy, usually available in the University Library, may contain corrections made by hand, which have been requested by the supervisor.

Synthetic studies of biologically active lignan and neolignan natural products

Claire Rye

A thesis submitted in partial fulfilment of the requirements
for the degree of Doctor of Philosophy in Chemistry.

The University of Auckland

2011

Abstract

Biologically active natural products have been of increasing interest to chemists due to the growing demand for new medicines. Lignans are a family of secondary plant metabolites known to exhibit both interesting biological activities and immense structural variety. This thesis describes the synthesis of a number of lignan and neolignan natural products and analogues thereof, with the overall aim of synthesising the complex dineolignan manassantin B **29**. The interest in **29** originates from its potent inhibition of the transcription factor HIF-1, which is a potential target for a new class of selective anticancer drugs targeting the hypoxic region common in solid tumours.

Initially, a series of 2,5-diaryl-3,4-dimethyl tetrahydrofuran lignans were synthesised *via* the strategy proposed for the synthesis of the more complex **29**. During the course of this work, it was found that varying the substrates in the final cyclisation step could significantly influence the products formed. This serendipitous discovery led to extensive investigation into the mechanisms controlling the reaction and the different compounds synthesised. With this knowledge three different subclasses of lignan were successfully synthesised, with the relative and absolute stereochemistry of a number of the natural compounds determined for the first time.

With the test synthesis proving successful the synthesis of **29** was undertaken *via* the envisaged convergent strategy, the three fragments *syn*-dimethyl compound **58** and two similar diaryl bromides **59** and **60** were synthesised enantioselectively and in pleasing yields. Unfortunately the fragments could not be joined using the established aryl lithium addition methodology which had proved very successful on the test substrates. Despite several modifications to the *syn*-dimethyl compound and adjusted strategies, the synthesis of manassantin B **29** remains elusive. The diaryl bromides **59** and **60** were however successfully employed in the synthesis of a series of 8,4'-oxyneolignans using a Suzuki-Miyaura strategy.

Selected synthetic natural products and analogues were sent to NCI for testing against a panel of the sixty common cancer cell lines. Whilst a further series of natural and analogous 8,4'-oxyneolignans were sent to the Swiss Tropical and Public Health Institute for evaluation against both leishmania and malaria.

Declaration

This is to certify that:

- 1) This thesis comprises only the authors original work, except where indicated below;
- 2) Due acknowledgment to all other material used has been made in the main text of the thesis

My overall contribution to the work presented in this thesis is approximately 98%, based on the following:

Chapter 8

Anticancer testing results shown were determined at the National Cancer Institute (NCI) USA.

Acknowledgements

Most importantly I would like to thank my supervisor David Barker. You have been a phenomenal mentor, a real inspiration and have had a pivotal role in my development as a chemist. I will be forever grateful for your guidance and support, your never ending list of ideas and positive attitude throughout. I am honoured to have been part of the Barker group for the last four years.

I am grateful to my co-supervisor Brent Copp, for your help deciphering the Crazies, as well as your guidance on a variety of subjects, with just a small amount of teasing.

I am also very obliged to my fume hood buddy Nora. You have been awesome to work alongside and I feel we make a great team in the lab, even if we don't clean up our silica often enough. I am also very grateful for your friendship, not to mention all the assistance you have given me with proofing!

Also to Lisa, who has been equally industrious with regard to proof reading. I have enjoyed our missions for NaCl and AcOH and the friendship that ensued, long may they continue.

The Barker and Copp groups past and present, thank you for making the west wing such a great working environment. For sharing the highs and lows with a collective sense of humour and much teasing, I will definitely miss the lab.

And finally, I am greatly indebted to my husband James for your love and support throughout. You still mean the world to me babe!

Table of Contents

Abstract.....	ii
Declaration.....	iii
Acknowledgements.....	iv
Abbreviations.....	viii
Chapter One: Introduction	1
1.0 Lignans.....	2
1.2 Biological activity of lignans	3
2.0 Tetrahydrofuran lignans.....	5
2.1 Biological activity of tetrahydrofuran lignans	5
2.2 Selected previous syntheses of tetrahydrofuran lignans	8
3.0 Manassantin B.....	11
3.1 Biological activity of manassantin B	11
3.2 Previous syntheses of manassantin B	12
4.0 Synthetic objectives	18
Chapter Two: Model tetrahydrofuran studies	21
2.1 Introduction.....	22
2.1.1 The acyl-Claisen rearrangement	23
2.1.2 Aryl lithium additions	27
2.1.3 Reduction and protection	30
2.1.4 Formation of aldehyde 96 and second aryl lithium additions.....	31
2.1.5 Cyclisation	33
2.1.6 Cyclisation of TBS protected alcohol 98.....	35
2.1.7 Cyclisation of MOM protected alcohol 110	36
2.1.8 Cyclisation to give the other stereochemistries	37
2.1.9 Conclusions.....	41
2.2 Synthesis of natural <i>trans trans trans</i> tetrahydrofuran lignans.....	45
2.2.1 Reduction, protection and synthesis of aldehyde 64.....	45
2.2.3 Second aryl lithium addition.....	46
2.2.4 Cyclisation and deprotection.....	46
2.3 Synthesis of tetrahydrofuran analogues	48
2.3.1 Aryl lithium additions and reduction	48
2.3.2 Protection and synthesis of aldehydes 144 and 145.....	50
2.3.3 Second aryl lithium addition.....	50
2.3.4 Cyclisation	51
2.4 Synthesis of saucermetin 64.....	55
2.4.1 Protection and synthesis of aldehyde 149.....	55
2.4.2 Second aryl lithium addition, with protection deprotection strategy	56
2.4.3 Cyclisation	57
2.5 Synthesis towards Hyperione A and B	58
2.5.1 Synthesis of starting materials	59
2.5.2 Acyl-Claisen rearrangement	60
2.5.3 Amide reduction.....	60
2.5.4 Reduction, protection and synthesis of aldehyde 173.....	62
2.5.5 Aryl lithium addition.....	62
2.5.6 Cyclisation	63
2.5.7 Benzylic oxidation	64
2.5.9 Conclusions and strategy reassessment	68
2.6 Summary and Conclusion	69

Chapter Three: Development of an asymmetric central fragment.....	71
3.1 Introduction.....	72
3.2 Attempt at an Enantioselective acyl-Claisen rearrangement	73
3.3 Other Claisen variants.....	74
3.3.2 The aza-Claisen rearrangement.....	75
3.3.3 Synthesis of starting materials	76
3.3.4 Attempting the aza-Claisen rearrangement.....	78
3.3.5 Cleaving the auxiliary	80
3.4 Conclusions.....	83
Chapter Four: Development of asymmetric side chain fragments.....	85
4.1 Initial strategy for the synthesis of bromides 59 and 60	86
4.1.1 Etherification following the procedure of Ley <i>et al.</i>	86
4.1.2 Etherification following the procedure of Curti <i>et al.</i>	88
4.2 Revised Strategy for the synthesis of diaryl bromides 59 and 60.....	89
4.2.1 Synthesis of ether 236 following the procedure of Curti <i>et al.</i>	89
4.3 Current synthetic strategy	90
4.3.1 Further optimisation of the etherification reaction	91
4.3.2 Synthesis of Aldehyde 240	92
4.3.3 Organometallic additions to Aldehyde 240	96
4.3.4 Oxidation and Reduction of alcohol 248	98
4.4 Conclusion	100
Chapter Five: Attempts towards the synthesis of manassantin B.....	101
5.1 Attempted addition of aryl bromide 59 to form ketone 254	102
5.2 Attempts at the aryl lithium additions to aldehydes.....	106
5.3 Attempts at the aryl lithium additions to central fragment aldehyde.....	111
5.4 Strategy reassessment	115
5.5 Attempted synthesis of manassantin B	117
5.6 Final strategy.....	119
5.7 Conclusions.....	120
Chapter Six: Synthesis of 8,4'-oxyneolignans	122
6.1 Summary of successful reactions with bromides 59 and 60.....	123
6.2 8,4'-oxyneolignans	123
6.2.1 Synthetic strategy.....	124
6.3 Suzuki-Miyaura reaction.....	126
6.4 Conclusion	131
Chapter Seven: Serendipitous cyclisation by-products.....	132
7.1 Introduction.....	133
7.1 Kadangustin J and K	134
7.2 Unexpected synthesis of dihydronaphthalene lignans during the attempted synthesis of Kadangustin J	136
7.3 Synthesis of pycnanthuligene A and B	139
7.4 Modified synthesis of kadangustin J.....	142
7.5 Synthesis of the unnamed <i>Schisandra</i> lignan	146
7.6 Conclusion	149
Chapter Eight: Biological testing.....	150
8.1 Biological testing	151
Chapter Nine: Summary and Future work	154
9.1 Summary	155
9.2 Future work.....	157
9.2.1 Future work towards Manassantin B	157

9.2.1 Other Future work.....	159
Chapter Ten: Experimental	161
General Details:	162
Synthesis of reagents:	163
Synthesis of compounds:	165
Appendix.....	318
Spectra of selected natural products:	318
NCI Testing Results.....	322
References:.....	333

Abbreviations

$^1\text{H-NMR}$	Proton nuclear magnetic resonance
2D	Two dimensional
9BBN-H	9-Borabicyclo[3.3.1]nonane
15-cr-5	15-crown-5
18-cr-6	18-crown-6
Ac ₂ O	Acetic anhydride
AcOH	Acetic acid
ALL	Acute lymphoblastic leukaemia
Ar	Aromatic
BDNF	Brain-derived nerve factor
BEMP	2- <i>tert</i> -Butylimino-2-dimethylamino-1,3-dimethyl-perhydro-1,3,2-diazosphine
CAN	Ceric ammonium nitrate
COSY	Correlation spectroscopy
DCC	<i>N,N'</i> -Dicyclohexylcarbodiimide
DCM	Dichloromethane
DDQ	Dichlorodicyanoquinone
de	Diastereomeric excess
DIBAL	Diisobutylaluminum hydride
DMAP	<i>N,N</i> -Dimethyl-4-aminopyridine
DME	Dimethoxyethane
DMP	Dess-Martin periodinane
DMF	Dimethylformamide
DMSO	Dimethylsulfoxide
DNA	Deoxyribonucleic acid
EAT	Ehrlich ascites tumour
ee	Enantiomeric excess
Et ₂ O	Diethyl ether
equiv.	Equivalents
FDA	Food and Drug Administration
HIF-1	Hypoxia inducible factor
HMDS	Hexamethyldisilane
HPLC	High pressure liquid chromatography
IBX	1-Hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide
IC ₅₀	Half maximal inhibitory concentration
<i>i</i> -PrOH	<i>iso</i> -Propanol
<i>i</i> Pr ₂ EtN	Diisopropylethylamine
IR	Infra-red
LDA	Lithium diisopropylamine
LHMDS	Lithium hexamethyldisilazane
Li(acac)	Lithium acetylacetonate
<i>m</i> -CPBA	<i>meta</i> -Chloroperoxybenzoic acid
MgBr ₂ ·OEt ₂	Magnesium bromide diethyl etherate
mech.	Mechanism
MeCN	Acetonitrile
MeOH	Methanol
NGF	Nerve growth factor
mol	Mole
MsCl	Methanesulfonyl Chloride

MOM	Methoxymethyl
MOMCl	Methoxymethyl chloride
MsCl	Methanesulfonyl chloride
<i>n</i> -BuLi	<i>n</i> -Butyllithium
NBS	<i>N</i> -Bromosuccinimide
NCI	National Cancer Institute
NEt ₃	Triethylamine
NMO	<i>N</i> -Methylmorpholine- <i>N</i> -oxide
NMP	<i>N</i> -Methyl-2-pyrrolidinone
NMR	Nuclear magnetic resonance
NOE	Nuclear Overhauser effect
NSCLC	Non-small cell lung cancer
PCC	Pyridinium chlorochromate
Pd ₂ (dba)	Palladium dibenzylideneacetone
Pd/C	Palladium on carbon
PPh ₃	Triphenylphosphine
PPTS	Pyridinium <i>para</i> -toluenesulfonate
PS-BEMP	2- <i>tert</i> -butylimino-2-dimethylamino-1,3-dimethyl-perhydro-1,3,2-diazophosphine on polystyrene
PS-BH ₄	Polymer supported- borohydride
quant.	Quantitative
Red-Al	Sodium bis(2-methoxyethoxy)aluminum hydride
Rf	Retention factor
rt	Room temperature
SM	Starting Material
S _N 1	Nucleophilic substitution (unimolecular)
S _N 2	Nucleophilic substitution (bimolecular)
TBAF	Tetrabutylammonium fluoride
TBAI	Tetrabutylammonium iodide
t _R	Retention time
<i>t</i> -BuLi	<i>t</i> -Butyllithium
<i>t</i> -BuOH	<i>t</i> -Butanol
TBS	<i>tert</i> -Butyl dimethylsilyl
TBSCl	<i>tert</i> -Butyl dimethylsilyl chloride
TBS-triflate	<i>tert</i> -Butyldimethylsilyl trifluoromethanesulfonate
tet	Tetrahedral
TES	Triethyl silyl
TESCl	Triethyl silyl chloride
THF	Tetrahydrofuran
TLC	Thin layer chromatography
TMS	Trimethylsilane
TMSOTf	Trimethylsilyl triflate
Ts ₂ O	Tosyl anhydride
TsCl	Tosyl chloride
VEGF	Vascular Epithelial Growth Factor